New drug duo targets Hard-to-Treat rare cancers
NCT ID NCT05142241
Summary
This study is testing whether a combination of two oral drugs, talazoparib and temozolomide, can shrink advanced rare cancers that have spread and for which standard treatments have stopped working. The trial aims to see if this drug pair can stop tumor growth by damaging cancer cell DNA and preventing its repair. It is for adults and some adolescents with specific rare solid tumors who have no other standard treatment options available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.